MX2017008277A - Solucion oftalmica acuosa. - Google Patents

Solucion oftalmica acuosa.

Info

Publication number
MX2017008277A
MX2017008277A MX2017008277A MX2017008277A MX2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A
Authority
MX
Mexico
Prior art keywords
ophthalmic solution
aqueous ophthalmic
concentration
aqueous
diquafosol
Prior art date
Application number
MX2017008277A
Other languages
English (en)
Inventor
Inagaki Koji
Ogawa Toshihiro
Nakazawa Hitoshi
Matsumoto Naoki
Wakabayashi Yukihisa
Kamimura Asuka
Oshita Yoshihiro
Matsuoka Isao
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56150716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017008277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2017008277A publication Critical patent/MX2017008277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C13/00—Assembling; Repairing; Cleaning

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se relaciona con una solución oftálmica acuosa que comprende diquafosol o una sal del mismo a una concentración del 0.1% al 10% (p/v) y una clorhexidina a una concentración del 0.0001% al 0.1% (p/v).
MX2017008277A 2014-12-25 2015-12-25 Solucion oftalmica acuosa. MX2017008277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014263003 2014-12-25
JP2015114595 2015-06-05
PCT/JP2015/086230 WO2016104704A1 (ja) 2014-12-25 2015-12-25 水性点眼液

Publications (1)

Publication Number Publication Date
MX2017008277A true MX2017008277A (es) 2017-10-02

Family

ID=56150716

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008277A MX2017008277A (es) 2014-12-25 2015-12-25 Solucion oftalmica acuosa.

Country Status (13)

Country Link
US (2) US10278985B2 (es)
JP (3) JP6779614B2 (es)
KR (3) KR101789019B1 (es)
AR (1) AR105199A1 (es)
BR (1) BR112017013841A2 (es)
CA (1) CA2971689C (es)
EA (1) EA034517B1 (es)
MX (1) MX2017008277A (es)
MY (1) MY182507A (es)
PH (1) PH12017501096A1 (es)
SG (1) SG11201705138QA (es)
TW (1) TWI709405B (es)
WO (1) WO2016104704A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101789019B1 (ko) * 2014-12-25 2017-10-20 산텐 세이야꾸 가부시키가이샤 수성 점안액
RU2742032C2 (ru) 2015-06-05 2021-02-01 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против сухости глаз, характеризуемое нанесением на глаза пациентов с сухостью глаз, носящих гибкие контактные линзы
TWI743858B (zh) * 2015-06-05 2021-10-21 日商參天製藥股份有限公司 使水性點眼液中之洛赫西定類安定化之方法
US20210000844A1 (en) * 2018-02-28 2021-01-07 Santen Pharmaceutical Co., Ltd. Ophthalmic composition comprising diquafosol and cationic polymer
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
US11229549B2 (en) * 2019-09-18 2022-01-25 Vance M. Thompson Tear transplantation and multi-part contact lens with absorbent portion
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
KR102365009B1 (ko) 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
TW202408467A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09301858A (ja) 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd グルコン酸クロルヘキシジン安定化水性薬剤
JPH10203960A (ja) * 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
JPH1160505A (ja) 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd 防腐組成物
JP2008222638A (ja) 2007-03-13 2008-09-25 Teika Seiyaku Kk 油成分含有眼用組成物
JP2009073788A (ja) 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
JP5398452B2 (ja) * 2008-09-30 2014-01-29 大正製薬株式会社 点眼剤
CN102470115B (zh) * 2009-08-07 2014-04-30 日本乐敦制药株式会社 硅酮水凝胶隐形眼镜用眼科组合物
JP6047272B2 (ja) 2010-09-15 2016-12-21 テイカ製薬株式会社 角膜上皮障害治療用点眼剤
MX2013007502A (es) * 2010-12-28 2013-08-01 Santen Pharmaceutical Co Ltd Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
IN2014DN08632A (es) * 2012-03-26 2015-05-22 Santen Pharmaceutical Co Ltd
KR101789019B1 (ko) 2014-12-25 2017-10-20 산텐 세이야꾸 가부시키가이샤 수성 점안액

Also Published As

Publication number Publication date
US20190209599A1 (en) 2019-07-11
KR20170067900A (ko) 2017-06-16
US10786526B2 (en) 2020-09-29
PH12017501096A1 (en) 2017-11-27
AR105199A1 (es) 2017-09-13
JP7128243B2 (ja) 2022-08-30
US20170348344A1 (en) 2017-12-07
KR101789019B1 (ko) 2017-10-20
KR20180063381A (ko) 2018-06-11
MY182507A (en) 2021-01-25
BR112017013841A2 (pt) 2018-06-19
TW201628626A (zh) 2016-08-16
SG11201705138QA (en) 2017-07-28
US10278985B2 (en) 2019-05-07
KR102330736B1 (ko) 2021-11-23
CA2971689A1 (en) 2016-06-30
EA201791467A1 (ru) 2017-11-30
JP6779614B2 (ja) 2020-11-04
JP2022166223A (ja) 2022-11-01
EA034517B1 (ru) 2020-02-17
KR101867791B1 (ko) 2018-06-15
TWI709405B (zh) 2020-11-11
JP2021008513A (ja) 2021-01-28
KR20170118255A (ko) 2017-10-24
JP2016210759A (ja) 2016-12-15
CA2971689C (en) 2020-11-03
WO2016104704A1 (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
PH12017501096A1 (en) Aqueous ophthalmic solution
CL2016003416A1 (es) Herbicidas de piperidinona
MY167716A (en) Drive device
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
IL262294A (en) Ophthalmic preparations containing levodopa, an antioxidant and a liquid carrier
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
ZA201800504B (en) Thickening agent for aqueous systems, formulations containing same and uses thereof
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EP3508200C0 (en) AQUEOUS FORMULATION CONTAINING 5-AMINOLEVULINIC ACID OR SIMILAR
CL2017000927A1 (es) Dispersiones acuosas estables de zinc fosfato
DK3634384T3 (da) Levodopa-infusionsopløsning
FR3030248B1 (fr) Association derive d'acide pyridine-dicarboxylique/agent anti-oxydant particulier
EP3448432A4 (en) TARGETED ADMINISTRATION OF AEROSOLS FROM MAGNETIZED ACTIVE SUBSTANCES
MX2020003768A (es) Composiciones acuosas herbicidas y metodos para usar las mismas.
FR3030531B1 (fr) Agent epaississant pour systemes aqueux, formulations le contenant et utilisations
GB201813579D0 (en) Aqueous solution
UA108358U (uk) Застосування похідних 2-амінооцтової кислоти як засобів протимікробної дії
UA120519U (uk) Використання похідних 4-амінобутанової кислоти як антиамнестичних засобів
CL2017000320S1 (es) Porción de carrete.
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
UA101964U (uk) Застосування декаметоксину як протимікробного засобу проти бактерій виду pseudomonas aeruginosa
UA92941U (uk) Застосування декаметоксину як протимікробного засобу проти бактерій роду bulkholderia
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6